{"filings":[{"id":94437,"accession_number":"0001193125-26-212426","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alector enters $125M ATM equity facility with TD Cowen","event_type":"other_material","confidence":"high","bullets":["May sell up to $125M of common stock from time to time through TD Cowen in at-the-market offerings.","TD Cowen will receive up to 3.0% of gross proceeds per share sold; no minimum sales obligation.","Proceeds intended for general corporate purposes, including R&D, manufacturing, and working capital.","Offered under effective shelf registration statement S-3 (File 333-294241) declared effective April 30, 2026.","Company may terminate agreement with 10 days' notice; contains standard representations and indemnities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94436,"accession_number":"0001193125-26-211918","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q1 net loss $22.9M ($0.21/sh); discontinues Phase 2 nivisnebart trial after futility","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.9M ($0.21/sh) vs $40.5M ($0.41) in Q1 2025; revenue $1.0M down from $3.7M.","Cash, cash equivalents, and investments $206.5M; runway expected through at least 2027.","Discontinued Phase 2 PROGRESS-AD trial of nivisnebart (AL101) in early AD after futility analysis.","ABC platform progress: AL037/AL137 (anti-Aβ) targeting IND in Q1 2027; AL050 (GCase ERT for PD) preclinical; AL164 (Tau siRNA) in IND-enabling studies.","R&D expenses decreased to $17.9M from $33.6M; G&A $8.1M from $14.7M due to workforce reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1046000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106819,"accession_number":"0001193125-26-071557","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q4 net loss $37.3M ($0.34/share); revenue down 89% YoY; cash $256M","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $37.3M vs $2.1M in Q4 2024; full-year net loss $142.9M ($1.39/share).","Collaboration revenue fell to $6.2M in Q4 from $54.2M a year earlier; full-year revenue $21M.","Cash, equivalents and investments $256M; company expects runway at least through 2027.","Independent interim futility analysis for PROGRESS-AD Phase 2 trial of nivisnebart expected H1 2026.","ABC-led pipeline advancing: AL137 IND filing planned Q4 2026/Q1 2027; AL050 IND target 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":21045000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123125,"accession_number":"0001193125-25-317554","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alector appoints Neil Berkley as CFO; he continues as CBO, effective Dec 10, 2025","event_type":"leadership","confidence":"high","bullets":["Neil Berkley named permanent CFO; had served as Interim CFO since June 2025.","Berkley remains Chief Business Officer; no change to existing compensation.","Berkley joined Alector in March 2024 as CBO; over 20 years biotech experience.","Press release issued Dec 12, 2025 confirming the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123124,"accession_number":"0001193125-25-269537","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q3 net loss $34.7M; cash $291.1M; selects lead candidates AL137, AL050; RIF 47%","event_type":"earnings","confidence":"high","bullets":["Net loss $34.7M ($0.34/sh) vs $42.2M ($0.43) in Q3 2024; revenue $3.3M, down from $15.3M.","Cash $291.1M, with $20M ATM proceeds Sep-Oct 2025; runway through 2027.","Lead candidates selected: AL137 (ABC anti-amyloid beta, IND 2026) and AL050 (ABC GCase, IND 2027).","Latozinemab Phase 3 INFRONT-3 failed; open-label extension discontinued.","Implemented ~47% workforce reduction in Oct 2025 to focus on priority programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":14808000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123123,"accession_number":"0001193125-25-245102","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","2.05","5.02","7.01","9.01"],"status":"ready","headline":"Alector's Phase 3 latozinemab trial fails; workforce cut 49%, R&D head resigns","event_type":"other_material","confidence":"high","bullets":["Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed clinical co-primary endpoint; biomarker endpoint met but no treatment effects seen.","Workforce reduction of ~49% (about 75 employees); restructuring charges ~$7.7M; completion expected by H1 2026.","President and Head of R&D Sara Kenkare-Mitra resigns effective Dec 22, 2025; separation includes 9 months salary and 50% bonus.","Preliminary cash, equivalents, and short-term investments ~$291.1M as of Sep 30, 2025; runway expected through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139807,"accession_number":"0000950170-25-105023","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alector Q2 net loss $30.5M; cash $307.3M; Phase 3 latozinemab data mid-Q4","event_type":"earnings","confidence":"high","bullets":["Net loss $30.5M ($0.30/sh) vs $38.7M ($0.40/sh) in Q2 2024; revenue $7.9M down from $15.1M.","Cash, cash equivalents, and investments $307.3M, providing runway into H2 2027.","On track to report topline data from INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN by mid-Q4 2025.","Guidance updated: collaboration revenue $13-18M, R&D expenses $130-140M, G&A $55-65M for FY2025.","Neil Berkley appointed interim CFO; USPTO issued patent for latozinemab treatment method."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":11548000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157395,"accession_number":"0001193125-25-140731","cik":1653087,"company_name":"Alector, Inc.","ticker":"ALEC","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Alector CFO Marc Grasso resigns; Neil Berkley named interim CFO","event_type":"leadership","confidence":"high","bullets":["CFO Marc Grasso resigns effective June 20; Neil Berkley, CBO, becomes interim CFO while continuing as CBO.","Grace Wong-Sarad appointed VP Accounting, serving as principal accounting officer.","Annual meeting elected directors Rosenthal and Hammond, ratified Ernst & Young, approved say-on-pay.","Cash runway into H2 2027; latozinemab Phase 3 top-line data expected Q4 2025.","Berkley base salary $455k, retention bonus $91k; Wong-Sarad base $343,636 (rising to $363,636), retention $54,545."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}